Endometrial Cancers Clinical Trial
Official title:
Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Endometrial Cancers
Ovarian cancer is the first mortality rate of gynecologic malignancies. The incidence of
ovarian cancer increased in recent 10 years and it has become the ninth cause of
malignancies in the women in Taiwan. From the above-mentioned data, ovarian cancer indeed is
a disease that should be respected, however, there were only few of research work focusing
on it in Taiwan. Despite the widespread use of aggressive cytoreductive surgery and the
introduction of chemotherapy regimens, the overall survival has changed little over the last
two decades. The basic problem in treating epithelial ovarian cancer is that once it has
spread beyond the ovary, it is exceedingly difficult to control and ultimately to cure. More
than 70% of ovarian cancer patients were advanced stage when diagnosed. To study the
mechanisms of carcinogenesis, progression, and metastasis of ovarian cancer will help us
understand this disease and develop new treatment strategies for ovarian cancer in the
future.
We have established an ascitogenic itnraperitoneal tumor cell line-WF3 in the mouse model in
our previous two-year project of NSC grant (grant number (NSC90-2314-B-002-457 and
NSC91-2341-B-002-315). Our group found that, mesothelin, this molecule is highly related
with the carcinogenesis, tumor progression and tumor metastasis in our animal model and
human cancer tissues. To further evaluate the role of mesothelin in ovarian cancer and
elucidate the potential of mesothelin as a target antigen for immunotherapy,
| Status | Recruiting |
| Enrollment | 250 |
| Est. completion date | December 2011 |
| Est. primary completion date | January 2007 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 15 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Patients with endometrial cancers who undergo hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and appendectomy will be enrolled and the clinical data will be obtained from our hospital. All of the patients received four to six courses of adjuvant platinum-containing chemotherapy.Histologic grading was according to International Union against Cancer criteria (28). The stage of disease was classified according to the International Federation of Gynecology and Obstetrics (FIGO, 1987). Pelvic and paraaortic lymph node samplings will be performed, if the disease will be confined to within the ovary or will be without a ruptured capsule. The histopathologic data, including histologic type and histologic grade, will be evaluated by a certified pathologist. The maximal diameter of the residual tumor after surgery will be also recorded. All patients will be followed up at 3-month intervals. |
Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | National Taiwan University Hospital | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| National Taiwan University Hospital |
Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | overall survival | from disease diagnosis to death | No |